FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088092675> ?p ?o ?g. }

• W2088092675 endingPage "167" @default.
• W2088092675 startingPage "161" @default.
• W2088092675 abstract "Objective Trabectedin in combination with PLD improves progression-free survival (PFS) and overall response rate (ORR) in comparison to PLD alone in patients with relapsed ovarian cancer (J Clin Oncol; 2010 28:3107-14). Here we report the impact of the treatment combination on patient-reported functional status and symptoms. Methods Patient-reported outcome (PRO) questionnaires, EORTC-QLQ C30, OV28, and EQ-5D were completed by patients at screening and on Day 1 of every other treatment cycle starting with Cycle 1, and at the end-of-treatment visit. Results Of the 672 patients randomized in this study, 663 treated patients completed at least one of the baseline questionnaires. Median cycles of treatment was 6 (131 days) for the combination arm and 5 (143 days) for the monotherapy arm. Longitudinal data analyses showed no significant differences between the treatment arms for any of the pre-specified scales. Similar analyses of other scales, including Health Index scores and Health State on the Visual Analog Scale, support these findings. Start of subsequent therapy was significantly delayed in the combination arm compared with the monotherapy arm (p=0.0032). Conclusions The addition of trabectedin to PLD led to little or no decrement in patient-reported functional status and symptoms in patients with relapsed ovarian cancer, as compared to treatment with PLD alone. The combination led to manageable and non‐cumulative overall toxicity with a fewer PLD-associated adverse events, and a significant improvement in PFS and ORR compared to single agent." @default.
• W2088092675 created "2016-06-24" @default.
• W2088092675 creator A5000978310 @default.
• W2088092675 creator A5007067879 @default.
• W2088092675 creator A5008763534 @default.
• W2088092675 creator A5014611244 @default.
• W2088092675 creator A5030257115 @default.
• W2088092675 creator A5051748951 @default.
• W2088092675 creator A5062762491 @default.
• W2088092675 creator A5065239318 @default.
• W2088092675 creator A5069247141 @default.
• W2088092675 creator A5077016336 @default.
• W2088092675 date "2012-10-01" @default.
• W2088092675 modified "2023-10-02" @default.
• W2088092675 title "Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone" @default.
• W2088092675 cites W120771606 @default.
• W2088092675 cites W1973560164 @default.
• W2088092675 cites W1979316002 @default.
• W2088092675 cites W1997112223 @default.
• W2088092675 cites W1999957443 @default.
• W2088092675 cites W2013709083 @default.
• W2088092675 cites W2018127153 @default.
• W2088092675 cites W2022747656 @default.
• W2088092675 cites W2029630138 @default.
• W2088092675 cites W2034945027 @default.
• W2088092675 cites W2046908893 @default.
• W2088092675 cites W2057913213 @default.
• W2088092675 cites W2060629938 @default.
• W2088092675 cites W2096593771 @default.
• W2088092675 cites W2097105130 @default.
• W2088092675 cites W2103152246 @default.
• W2088092675 cites W2125064537 @default.
• W2088092675 cites W2129949847 @default.
• W2088092675 cites W2130941707 @default.
• W2088092675 cites W2133565458 @default.
• W2088092675 cites W2139171257 @default.
• W2088092675 cites W2143219457 @default.
• W2088092675 cites W2154175915 @default.
• W2088092675 cites W2167571044 @default.
• W2088092675 cites W2171318838 @default.
• W2088092675 cites W2328421677 @default.
• W2088092675 cites W4211147776 @default.
• W2088092675 doi "https://doi.org/10.1016/j.ygyno.2012.06.034" @default.
• W2088092675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22765965" @default.
• W2088092675 hasPublicationYear "2012" @default.
• W2088092675 type Work @default.
• W2088092675 sameAs 2088092675 @default.
• W2088092675 citedByCount "40" @default.
• W2088092675 countsByYear W20880926752012 @default.
• W2088092675 countsByYear W20880926752013 @default.
• W2088092675 countsByYear W20880926752014 @default.
• W2088092675 countsByYear W20880926752015 @default.
• W2088092675 countsByYear W20880926752016 @default.
• W2088092675 countsByYear W20880926752017 @default.
• W2088092675 countsByYear W20880926752018 @default.
• W2088092675 countsByYear W20880926752019 @default.
• W2088092675 countsByYear W20880926752021 @default.
• W2088092675 countsByYear W20880926752022 @default.
• W2088092675 countsByYear W20880926752023 @default.
• W2088092675 crossrefType "journal-article" @default.
• W2088092675 hasAuthorship W2088092675A5000978310 @default.
• W2088092675 hasAuthorship W2088092675A5007067879 @default.
• W2088092675 hasAuthorship W2088092675A5008763534 @default.
• W2088092675 hasAuthorship W2088092675A5014611244 @default.
• W2088092675 hasAuthorship W2088092675A5030257115 @default.
• W2088092675 hasAuthorship W2088092675A5051748951 @default.
• W2088092675 hasAuthorship W2088092675A5062762491 @default.
• W2088092675 hasAuthorship W2088092675A5065239318 @default.
• W2088092675 hasAuthorship W2088092675A5069247141 @default.
• W2088092675 hasAuthorship W2088092675A5077016336 @default.
• W2088092675 hasConcept C121608353 @default.
• W2088092675 hasConcept C126322002 @default.
• W2088092675 hasConcept C126894567 @default.
• W2088092675 hasConcept C136948725 @default.
• W2088092675 hasConcept C141071460 @default.
• W2088092675 hasConcept C143998085 @default.
• W2088092675 hasConcept C168563851 @default.
• W2088092675 hasConcept C197934379 @default.
• W2088092675 hasConcept C203092338 @default.
• W2088092675 hasConcept C2776694085 @default.
• W2088092675 hasConcept C2776999253 @default.
• W2088092675 hasConcept C2778629024 @default.
• W2088092675 hasConcept C2780427987 @default.
• W2088092675 hasConcept C2780752271 @default.
• W2088092675 hasConcept C29730261 @default.
• W2088092675 hasConcept C31760486 @default.
• W2088092675 hasConcept C71924100 @default.
• W2088092675 hasConceptScore W2088092675C121608353 @default.
• W2088092675 hasConceptScore W2088092675C126322002 @default.
• W2088092675 hasConceptScore W2088092675C126894567 @default.
• W2088092675 hasConceptScore W2088092675C136948725 @default.
• W2088092675 hasConceptScore W2088092675C141071460 @default.
• W2088092675 hasConceptScore W2088092675C143998085 @default.
• W2088092675 hasConceptScore W2088092675C168563851 @default.
• W2088092675 hasConceptScore W2088092675C197934379 @default.
• W2088092675 hasConceptScore W2088092675C203092338 @default.
• W2088092675 hasConceptScore W2088092675C2776694085 @default.
• W2088092675 hasConceptScore W2088092675C2776999253 @default.

• next